ClinicalTrials.gg
RecruitingNCT07032961Updated Jul 4, 2025

A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening

An observational study in Gastritis, Gastric Dysplasia and Gastric Ulcer, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Nanfang Hospital, Southern Medical University · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Gastritis with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Gastritis · China.

Started
2025
with 6 others
Observational
9 of 31
4 open now
Registered
28th of 31
by date
Lead sponsor
2 of 31
Nanfang Hospital, Southern Medical University

Among the 31 studies in Gastritis with a site in China, this one is one of 7 that started in 2025, is one of 9 observational ones, and was the 28th registered.

Gastritis

136 studies on the registry are indexed under Gastritis; 24 are open to participants now.

Browse Gastritis studies →

Open to participants now

7 of the 31 studies in Gastritis with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 45 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Gastritis with a site in China, or all of them as a file.
02

Study summary

The goal of this is to learn about the effectiveness and feasibility of a novel AI- assisted Mobile Capsule Gastroscopy (MCG) system for detecting gastric pathologies in elderly and high-risk populations.

The main question it aims to answer is:

Can MCG effectively detect gastric pathologies, including common gastric diseases, gastric cancer, and precancerous lesions, in elderly and high-risk individuals at community health centers?

Participants will:

Epidemiological, diagnostic, and post-MCG follow-up data generated during participants' involvement in the gastric pathologies public screening program will be collected.

Read the detailed description

Gastric diseases-including atrophic gastritis, gastric polyps, peptic ulcers, submucosal lesions, gastric cancer, and precancerous conditions-have become a major global public health challenge. In China, the prevalence of gastric ulcers is as high as 17.2%, significantly higher than that in Western countries (4.1%) [1]. Gastric cancer also ranks among the top globally in both incidence and mortality, with approximately 400,000 new cases and over 300,000 deaths each year [2-3]. Notably, around 80% of patients are diagnosed at an advanced stage, and the 5-year survival rate is less than 30% [4]. Studies have shown that early gastric cancer, if detected and treated promptly, can achieve a 5-year survival rate of over 90% [5]. Moreover, if benign conditions such as atrophic gastritis and peptic ulcers are not treated in time, they may progress into precancerous lesions or even malignancies [6]. Therefore, early screening and accurate diagnosis are key to reducing the disease burden of gastric disorders.

Although esophagogastroduodenoscopy (EGD) is considered the gold standard for gastric disease screening [7-8], its invasive nature, associated patient discomfort, and reliance on skilled endoscopists and specialized equipment limit its accessibility. In China, the scarcity of endoscopic resources in primary care settings, combined with low patient compliance, further restricts screening coverage and increases the risk of missed diagnoses [9-10].

In recent years, capsule endoscopy has emerged as a valuable complementary tool for gastrointestinal disease screening due to its non-invasive and user-friendly nature [6,7]. Among its modalities, magnetically controlled capsule gastroscopy (MCCG) provides comprehensive gastric visualization, with reported sensitivity and specificity of 90% and 92%, respectively, for common gastric lesions. However, its reliance on expensive magnetic navigation systems and trained operators limits its widespread adoption in community-based screening programs [8].

To address these limitations, a novel mobile-controlled capsule gastroscopy (MCG) system being more accessible and not requiring costly external magnetic control was developed. It consists only of a disposable capsule and a wireless portable receiver. Participants can complete the examination independently in community health centers or at home by following video instructions via a smartphone app and adjusting their body positions to guide the capsule. An AI algorithm ensures complete gastric coverage in real time. The video can be viewed directly on the smartphone and transmitted to the cloud for remote diagnosis. The MCG system is non-invasive, user-friendly, and compatible with remote diagnosis, making it well suited for gastric disease screening in community health centers. Compared with MCCG, MCG enables fully autonomous operation without magnetic navigation, substantially reducing technical complexity and healthcare costs. However, its diagnostic accuracy and real-world feasibility in community-based populations have yet to be validated through prospective studies.

In 2025, the Guangzhou Municipal Health Commission issued the 'Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality'. Organized by the Commission and led by Southern Medical University Nanfang Hospital, with participation from Guangzhou First People's Hospital, The Second Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Hospital of Traditional Chinese Medicine, and others, the program will conduct screening and surveillance of 10,000 elderly and high-risk individuals in community health centers across Guangzhou.

This prospective cohort study will collect epidemiological data, examination results, follow-up outcomes, and other relevant information from the screening program. The primary endpoint is the detection rate of gastric pathologies, including common conditions (such as atrophic gastritis, gastric ulcers, and submucosal tumors), gastric cancer, and precancerous lesions. The operational feasibility, safety, and acceptability of the MCG system in primary care settings will also be assessed. Findings are expected to provide scientific evidence to support the optimization of gastric disease prevention and control strategies at the municipal level.

1. Baseline Period

  1. Record demographic data: gender, age
  2. Record medical history and physical examination: including vital signs, anthropometric data (height and weight), comprehensive systemic assessment, history of smoking and alcohol use, Helicobacter pylori infection status, prior gastric pathologies, family history of gastric cancer, and mode of transportation to the clinic.

2. Diagnostic \& Therapeutic Procedures

  1. Record laboratory tests (if available), including complete blood count, stool analysis, prothrombin time, and the ¹³C/¹⁴C urea breath test.
  2. Record the results of the MCG, the anatomical coverage of gastric regions, the rate of device failure and the overall image quality of the examination.
  3. Record findings and therapeutic interventions from esophagogastroduodenoscopy (EGD) and histopathological biopsy results (if available).

3. Follow-up prognostic data

  1. Record short-term follow-up data, including capsule endoscopy expulsion status, adverse events, referral outcomes, subsequent treatment, and patient compliance.
  2. Record long-term follow-up data, including gastric pathologies incidence and survival rates of project participants.

3.1 Short-term follow-up will be conducted on Days 1, 3, and 14 following MCG.

  1. Participants are instructed to inspect stool for capsule excretion and report the time of passage. If the capsule is not passed within 72 hours and gastrointestinal symptoms occur (e.g., constipation, abdominal pain), the research team will arrange clinical evaluation. Capsule retention will be confirmed via abdominal X-ray or CT. Management may include prokinetic therapy or surgical retrieval as needed; the study will be discontinued post-retrieval in such cases.
  2. All participants will receive a report summarizing the findings of the MCG examination. Researchers from community centers will follow up with individuals whose reports indicate significant gastric abnormalities to facilitate further medical management. Additionally, the overall study findings will be disseminated through publication in a peer-reviewed scientific journal.

3.2 Long-term follow-up will be conducted annually for a duration of five years through telephone interviews and/or routine monitoring at community health centers.

03

Conditions studied

  • Gastritis
  • Gastric Dysplasia
  • Gastric Ulcer
  • Gastric Cancer
  • Gastric Mass

Keywords

  • Capsule Endoscopy
  • Prospective Study
  • screening
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

10,000 participants enrolled in the existing public welfare screening program: Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Provision of written ; 2.Participants of the 'Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality', the following are the criteria for inclusion in this public welfare programme:

  1. Elderly cohort: Permanent residents of Guangzhou aged ≥60 years who have not undergone specialized gastric disease screening in the past three years;
  2. Or high-risk cohort: Individuals aged ≥45 years who meet at least one of the following risk criteria:

    1. History of Helicobacter pylori infection (positive ¹³C/¹⁴C urea breath test);
    2. Prior diagnosis of chronic atrophic gastritis, gastric ulcer, neoplastic gastric polyps, hypertrophic gastritis, or pernicious anemia;
    3. Family history of gastric cancer (first-degree relative with a confirmed diagnosis);
    4. Long-term high-salt diet, smoking history (≥20 pack-years), or heavy alcohol consumption (100 mL of distilled spirits/day).

Exclusion criteria

Exclusion Criteria:

  1. Not considered by the investigator to be suitable for participation in this study.
  2. Meets the exclusion criteria of the Public Welfare Programme. Individuals will be excluded if they meet any of the following conditions:

(1)Known allergy to medical polymer materials; (2)Psychiatric disorders that interfere with procedural cooperation; (3)Pregnancy or lactation; (4)Severe systemic comorbidities (e.g., cardiovascular, respiratory, neurological diseases) affecting examination tolerance; (5)Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or gastrointestinal diverticulosis; (6)Known or suspected gastrointestinal malformations, obstructions, strictures, or fistulas; (7) dysphagia; (8)Acute abdominal symptoms (e.g., pain, vomiting, suspected bowel obstruction, or severe constipation); (9)History of major gastrointestinal surgery (e.g., esophagogastrostomy, gastrojejunostomy); (10)Physical debilitation precludes postural changes or concurrent severe illness; (11)Medically ineligible for abdominal procedures or refusal to undergo them; (12)Deemed unsuitable for MCG by the investigator; (13)Refusal to provide ; (14)Any other condition judged by the investigator to make the individual unsuitable for study participation.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Enrolment Group

    The enrolment group includes all subjects who will undergo MCG examination in the 'Gastric pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality'.

    Other: Collect epidemiological, diagnostic, and follow-up data after MCG examination.

Interventions

  • OtherCollect epidemiological, diagnostic, and follow-up data after MCG examination.

    MCG System: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.

06

What researchers measure

Primary outcomes

  1. Detection Rate of Gastric Diseases Using Mobile Capsule Gastroscopy

    This measure assesses the proportion of participants in whom MCG identifies common gastric diseases, gastric cancer, or precancerous lesions.

    Time frame: At end of data collection phase (within 6 months of study launch)

Secondary outcomes

  1. Safety of MCG

    This outcome tracks the incidence and types of adverse events related to the MCG procedure, including capsule retention, discomfort, or complications requiring medical intervention.

    Time frame: Within 14days after MCG procedure

  2. Quality of MCG Examination

    The coverage rate of gastric anatomical regions, the device failure rate, image quality, and mucosal visibility will be evaluated for all MCG examinations. Coverage for each anatomical region and overall gastric coverage will be calculated as: Coverage rate = Number of Regions Adequately Visualized / Total Number of Anatomical Regions The calculation formula for the incidence of device failure is as follows: Device failure rate = Number of Cases with Device Failure / Number of Cases. A three-level grading scale (excellent / good / poor) will be used to objectively assess the following imaging quality indicators: clarity, field of view, image stability, structural and detail resolution, stereoscopic perception, overall image impression, intragastric cleanliness, gastric lumen distension, and mucosal visualization.

    Time frame: At end of data collection phase (within 6 months of study launch)

  3. Procedural Compliance and Completion Rate

    This outcome evaluates the proportion of participants who successfully complete the MCG exam without technical failure or early termination.

    Time frame: Immediately after MCG procedure

  4. Patient Satisfaction

    Participant-reported satisfaction with the MCG procedure, assessed via structured survey covering aspects such as comfort and convenience.

    Time frame: Immediately after MCG procedure

  5. Cost-Effectiveness of MCG Screening

    Evaluates the cost per case of gastric pathologies detected using MCG versus conventional methods, using health economic metrics such as cost-effectiveness ratio and incremental cost-effectiveness ratio (ICER).

    Time frame: At end of data collection phase (within 6 months of study launch)

  6. Diagnostic Agreement Between MCG and EGD (Kappa Value)

    Measures the consistency of diagnosis between MCG and the gold-standard EGD in participants with suspicious MCG findings. The Kappa statistic will be calculated to quantify diagnostic agreement.

    Time frame: Within 30 days after MCG for participants referred for confirmatory EGD

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 24, 2025
StartActual
Jun 24, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2030
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07032961
Collaborators
Guangzhou First People's Hospital, Second Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Hospital of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Jun 24, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Jul 4, 2025

Study contacts

Xiaobei Luo
Contact
luoxiaobei63@126.com
+86 17688881428

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion